What are the rules governing cannabis and psychedelics in Australia? How have attitudes to these substances changed over time, and what does the Australian biotech industry need governments to do to unlock the myriad therapeutic benefits they promise?
Emyria Ltd (ASX:EMD)'s Dr Michael Winlo answers these questions and more in this interview with Proactive's Susanna Nelson.